TABLE 3.
Serotype distribution of pneumococcal respiratory tract isolates in Germany
| Serotype | No. (%) of all strains | Subgroup of strains
|
|||||
|---|---|---|---|---|---|---|---|
| No. (%) of childrena | No. (%) of children with otitis media | No. (%) of adultsb | Strains with resistance [no. (%)] to:
|
||||
| Penicillin Gc | Clarithromycin | Tetracycline | |||||
| 1 | 4 (1.0) | 3 (0.9) | 3 (4.3) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) |
| 3 | 15 (3.6) | 14 (4.3) | 5 (7.2) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) |
| 4 | 4 (1.0) | 4 (1.2) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 5 | 2 (0.5) | 2 (0.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 6A | 41 (9.9) | 37 (11.4) | 4 (5.8) | 2 (2.7) | 5 (8.1) | 3 (4.4) | 3 (3.3) |
| 6B | 51 (12.3) | 38 (11.7) | 5 (7.2) | 14 (18.9) | 17 (27.4) | 19 (27.9) | 23 (25.0) |
| 7F | 3 (0.7) | 3 (0.9) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 8 | 3 (0.7) | 2 (0.6) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 9A | 3 (0.7) | 2 (0.6) | 1 (1.4) | 1 (1.4) | 1 (1.6) | 0 (0) | 0 (0) |
| 9L | 3 (0.7) | 1 (0.3) | 0 (0) | 2 (2.7) | 0 (0) | 0 (0) | 1 (1.1) |
| 9N | 4 (1.0) | 3 (0.9) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) |
| 9V | 8 (1.9) | 7 (2.2) | 2 (2.9) | 1 (1.4) | 4 (6.5) | 1 (1.5) | 0 (0) |
| 10A | 10 (2.4) | 9 (2.8) | 1 (1.4) | 1 (1.4) | 1 (1.6) | 0 (0) | 0 (0) |
| 11A | 13 (3.1) | 10 (3.1) | 1 (1.4) | 3 (4.1) | 1 (1.6) | 0 (0) | 0 (0) |
| 11C | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 12F | 3 (0.7) | 2 (0.6) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) |
| 13 | 3 (0.7) | 1 (0.3) | 0 (0) | 2 (2.7) | 1 (1.6) | 0 (0) | 0 (0) |
| 14 | 17 (4.1) | 15 (4.6) | 5 (7.2) | 2 (2.7) | 1 (1.6) | 8 (11.8) | 2 (2.2) |
| 15A | 6 (1.4) | 3 (0.9) | 2 (2.9) | 1 (1.4) | 2 (3.2) | 1 (1.5) | 2 (2.2) |
| 15B | 9 (2.2) | 7 (2.2) | 2 (2.9) | 2 (2.7) | 2 (3.2) | 0 (0) | 0 (0) |
| 15C | 5 (1.2) | 5 (1.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 15F | 5 (1.2) | 3 (0.9) | 0 (0) | 1 (1.4) | 1 (1.6) | 1 (1.5) | 1 (1.1) |
| 16F | 3 (0.7) | 3 (0.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 17F | 5 (1.2) | 5 (1.5) | 0 (0) | 0 (0) | 2 (3.2) | 0 (0) | 0 (0) |
| 18B | 1 (0.2) | 0 (0) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) |
| 18C | 7 (1.7) | 7 (2.2) | 4 (5.8) | 0 (0) | 0 (0) | 1 (1.5) | 0 (0) |
| 19A | 13 (3.1) | 9 (2.8) | 4 (5.8) | 4 (5.4) | 7 (11.3) | 4 (5.9) | 4 (4.3) |
| 19B | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) | 0 (0) | 1 (1.5) | 1 (1.1) |
| 19F | 76 (18.3) | 55 (17.0) | 15 (21.7) | 14 (18.9) | 7 (11.3) | 11 (16.2) | 29 (31.5) |
| 21 | 3 (0.7) | 1 (0.3) | 0 (0) | 1 (1.4) | 2 (3.2) | 0 (0) | 1 (1.1) |
| 22F | 3 (0.7) | 3 (0.9) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 23A | 3 (0.7) | 3 (0.9) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 23F | 58 (14.0) | 42 (13.0) | 8 (11.6) | 13 (17.6) | 6 (9.7) | 15 (22.1) | 19 (20.7) |
| 24A | 1 (0.2) | 0 (0) | 0 (0) | 0 (0) | 1 (1.6) | 1 (1.5) | 1 (1.1) |
| 24F | 2 (0.5) | 1 (0.3) | 0 (0) | 1 (1.4) | 0 (0) | 0 (0) | 1 (1.1) |
| 28A | 1 (0.2) | 1 (0.3) | 1 (1.4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 31 | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 33C | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 33F | 2 (0.5) | 2 (0.6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 34 | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 35C | 1 (0.2) | 1 (0.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 35F | 3 (0.7) | 2 (0.6) | 0 (0) | 0 (0) | 1 (1.6) | 0 (0) | 0 (0) |
| 38 | 3 (0.7) | 3 (0.9) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 46 | 1 (0.2) | 0 (0) | 0 (0) | 1 (1.4) | 0 (0) | 1 (1.5) | 1 (1.1) |
| Rough | 12 (2.9) | 10 (3.1) | 1 (1.4) | 3 (4.1) | 0 (0) | 1 (1.5) | 3 (3.3) |
| Total | 415 (100) | 324 (100) | 69 (100)d | 74 (100) | 62 (100) | 68 (100) | 92 (100) |
Children <5 years of age.
Individuals >18 years of age.
Strains include penicillin-intermediate and -resistant isolates.
Coverage of 23-valent vaccine, 81.1%